A Phase 1a/1b Study of LY3415244, a Bispecific Antibody in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs LY 3415244 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 08 Nov 2019 Status changed from active, no longer recruiting to discontinued.
- 16 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Sep 2019 Planned End Date changed from 31 Oct 2020 to 9 Oct 2019.